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Summary
The use of allogeneic haematopoietic stem cell transplantation (Allo-HSCT)
is a standard treatment option for many patients with haematological
malignancies. Historically, patients requiring intensive care unit (ICU)
admission for transplant-related toxicities have fared extremely poorly, with
high ICU mortality rates. Little is known about the impact of reduced
intensity Allo-HSCT conditioning regimens in older patients on the ICU
and subsequent long-term outcomes. A retrospective analysis of data
collected from 164 consecutive Allo-HSCT recipients admitted to ICU for a
total of 213 admissions, at a single centre over an 115-year study period
was performed. Follow-up was recorded until 31 March 2011. Autologous
HSCT recipients were excluded. In this study we report favourable ICU
survival following Allo-HSCT and, for the first time, demonstrate signifi-
cantly better survival for patients who underwent Allo-HSCT with reduced
intensity conditioning compared to those treated with myeloablative condi-
tioning regimens. In addition, we identified the need for ventilation (inva-
sive or non-invasive) as an independently significant adverse factor
affecting short-term ICU outcome. For patients surviving ICU admission,
subsequent long-term overall survival was excellent; 61% and 51% at 1 and
5 years, respectively. Reduced intensity Allo-HSCT patients admitted to
ICU with critical illness have improved survival compared to myeloablative
Allo-HSCT recipients.
Keywords: intensive care, allogeneic haematopoietic stem cell transplanta-
tion, transplant toxicity, long term outcome.
Allogeneic haematopoietic stem cell transplantation (Allo-
HSCT) offers a chance of cure for many haematological
malignancies. Standard myeloablative (MA) conditioning
regimens are designed for maximal anti-tumour effect. Such
approaches are associated with considerable morbidity and
mortality due to treatment-related toxicities (overwhelming
infection, end-organ failure and graft-versus-host disease
[GvHD]), which increase with recipient age, extent of prior
treatment, disease-related end-organ damage and concomi-
tant diseases.
Transplant-related complications necessitate ICU admis-
sion in a significant proportion of patients undergoing Allo-
HSCT (Naeem et al, 2006; Scales et al, 2008). Previously
published survival rates for patients admitted to ICU follow-
ing HSCT (both allogeneic and autologous) have been very
poor with an in-hospital mortality rate of 54–96%, while the
reported mortality rates for ventilated HSCT patients in these
studies have been extremely high at 81–96% (Afessa et al,
1992; Faber-Langendoen et al, 1993; Rubenfeld & Crawford,
1996; Jackson et al, 1998; Paz et al, 1998; Price et al, 1998;
Bach et al, 2001; Scales et al, 2008).
Following the introduction of reduced intensity (RI) con-
ditioning regimens 20 years ago, there has been an expansion
of allogeneic transplantation in older patients. RI regimens
do not rely on cytotoxic measures to ablate recipient haemat-
opoietic cells but are highly immunosuppressive. This per-
mits the engraftment of donor-derived cells alongside
residual recipient cells in a transient state of immunological
tolerance. Such regimens commonly include fludarabine
combined with monoclonal antibodies directed against T
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cells and/or low-dose total body irradiation (TBI). Removal
of T cells from the donor stem cell preparation [T-cell deple-
tion, (TCD)], to reduce GvHD with subsequent add-back of
donor lymphocytes to provide anti-tumour immune
responses, is also employed. Success has been demonstrated
in a range of haematological malignancies (Morris & Mack-
innon, 2005; Craddock, 2008; Thomson et al, 2010; Peggs
et al, 2011). Such approaches have reduced the immediate
transplant-related mortality (TRM) due to less toxic condi-
tioning chemo/radiotherapy but, as a result of increased and
prolonged immune suppression, infective complications may
be more common in the post-transplant period (Martino
et al, 2009). Such prolonged immune suppression in older
adults, with worse pre-transplant co-morbidity scores, may
be predicted to result in increased respiratory infections and/
or ICU referral.
Many studies have evaluated the outcome of critically ill
haematology patients, but only a few large studies have
focussed solely on the outcome of Allo-HSCT recipients
requiring ICU admission (Pene et al, 2006; Depuydt et al,
2011). In these studies, <10% of patients received RI condi-
tioning and there are very limited published data directly
comparing ICU outcomes for RI and MA Allo-HSCT recipi-
ents. This is increasingly important as, in the UK, the major-
ity of allogeneic transplants now utilize RI conditioning (K
Kirkland, British Society of Blood and Marrow Transplanta-
tion [BSBMT] Data Registry, Guy’s Hospital, London,
personal communication). In addition, there are only a few
published studies considering the long-term survival of Allo-
HSCT admitted to ICU, which reported survival at 1 year or
beyond (Pene et al, 2006; Lim et al, 2007; Scales et al, 2008;
Bokhari et al, 2010).
The primary aim of this study was to determine the short
and long-term outcomes of patients admitted to the ICU in
our institution following Allo-HSCT over an 115-year per-
iod. We assessed whether RI regimens were associated with
improved ICU and long-term survival, and determined
whether there were are any factors predictive of outcome.
Materials and methods
Patients and setting
A retrospective analysis of data collected from 164 consecu-
tive adult and adolescent Allo-HSCT recipients admitted to
the critical care unit for a total of 213 admissions, at a single
centre, University College London Hospitals NHS Founda-
tion Trust (UCLH), between June 1996 and December 2007
was performed. Follow-up was recorded until 31 March
2011. Autologous HSCT recipients were excluded. The criti-
cal care unit is mixed-dependency, caring for both level 2
(High Dependency Unit – HDU) and level 3 (ICU) patients.
All Allo-HSCT patients admitted to this unit were included
in the analysis. Intensive care physicians share responsibility
of care with admitting transplant haematologists. The critical
care unit routinely admits critically ill immuno-compromised
patients and is the only location in the hospital offering
organ support, such as mechanical ventilation, vasoactive
drugs and renal replacement therapy.
Data collection
The following demographic variables, haematological disease-
related and transplant-related characteristics were recorded:
age, sex and year of ICU admission, underlying haematologi-
cal disease, conditioning regimen, GvHD prophylaxis, condi-
tioning regimen intensity – myeloablative (MA) or reduced
intensity (RI), and type of donor (sibling or unrelated). Fac-
tors studied in relation to the severity of illness requiring
admission to ICU were: number of ICU admissions, reason
for admission, number and modality of organ support, Acute
Physiology and Chronic Health Evaluation (APACHE II)
score, and length of ICU stay. Laboratory-based parameters
on day of ICU admission analysed were: neutrophil count,
platelet count, serum bilirubin and urea. Time from Allo-
HSCT to ICU admission was recorded. Data were retrieved
from patient case notes, the UK Intensive Care National
Audit and Research Centre database and the UCLH Clinical
Data Repository. Long-term follow-up data were obtained
from transplant clinics, medical records, and primary care
physicians.
Definitions
The following terms were used as indications for admission
to ICU and are defined below: sepsis, respiratory, renal,
haemodynamic, neurological, acute respiratory distress syn-
drome, and acute lung injury. Sepsis: Sepsis was defined by
the presence of a systemic inflammatory response syndrome
(SIRS) with a concurrent documented or assumed infection
(Bone et al, 2009). Respiratory: Respiratory failure included
type I and type II failure. Renal: Renal admissions to ICU
were defined by the need for renal replacement therapy. Hae-
modynamic: Admissions for the purposes of invasive cardio-
vascular monitoring with or without inotropic support were
defined as haemodynamic. Neurological: Admissions with a
Glasgow Coma Scale (GCS) score of 8 or less. The APACHE
II tool is a widely used illness severity scoring system based
on three variables; the worst physiological derangement
recorded within the first 24 h of ICU admission, age and
chronic health status (Knaus et al, 1985; Afessa et al, 2003).
End points
ICU and long-term survival were analysed ‘by patient’. For
those patients who were admitted to ICU more than once,
outcome and survival were analysed from their last ICU
admission. Long-term outcome was assessed by mortality
rates of ICU survivors at latest follow-up. Cause of death was
identified from the medical notes and/or post mortem
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examination results where available. Other standard end-
points analysed were TRM (non-relapse mortality related
directly to the Allo-HSCT) and relapse of the underlying
haematological malignancy (confirmed by clinical findings
and histopathological examination).
Statistical analysis
Effects on survival during an ICU admission were compared
by logistic regression. Overall survival was calculated by
Kaplan–Meier analysis and comparisons of survival were made
by the log-rank test (for binary variables) and Cox regression
(for categorical variables with more than two categories). P
values < 005 were considered statistically significant. Ninety-
five per cent confidence intervals (95% CI) are shown for
survival analyses. Multivariate analysis of overall survival was by
Cox regression. The multivariate model used included all terms
significant or trend (P < 01) to univariate analysis and then
eliminated non-significant terms.
Results
Patient demographics and transplantation type
Patient demographics, disease characteristics and transplant
details are summarized in Table I. A total of 164 Allo-HSCT
patients were included in the study. Median follow-up of all
surviving patients was 43 months (range 4–101), with a med-
ian follow-up of 30 months (12–101) for MA patients and
45 months (9–69) for RI patients (P = 07111).
The median age of patients at last admission to ICU was
41 years (range 11–66) and the recipients of RI Allo-HSCT
were significantly older at 50 years (range 23–66) compared
to MA Allo-HSCT patients at 39 years (range 11–60),
P = 00001. The cohort included 12 adolescent patients aged
11–17 years. Sixty percent of patients were male, with no
significant difference between the MA and RI groups. Trans-
plants were performed for a range of haematological malig-
nancies. One hundred and twenty-seven patients (77%) were
admitted to ICU following MA Allo-HSCT and 37 (23%)
following RI Allo-HSCT.
As per our standard clinical practice, the majority of
patients underwent T cell depleted (TCD) Allo-HSCT. RI
Allo-HSCT patients were conditioned with fludarabine,
melphalan and in vivo alemtuzumab (FMC), whilst MA
Allo-HSCT patients were conditioned either with total body
irradiation (TBI), fludarabine, cyclophosphamide and ex vivo
alemtuzumab. A small number of MA Allo-HSCT patients
were conditioned with TBI and cyclophosphamide or etopo-
side (T-replete). GvHD prophylaxis was ciclosporin alone, at
3 mg/kg per day starting on day 1 with a target level of
150–200 ng/ml (additional short-course methotrexate was
given to patients receiving T-replete MA transplants). In the
absence of GvHD, ciclosporin was tapered from 3 months
after transplantation. Acute and chronic GvHD were graded
according to standard consensus criteria. Supportive care was
given according to local policy and escalated as clinically
appropriate. Patients at risk of cytomegalovirus re-activation
were monitored by weekly quantitative polymerase chain
reaction and pre-emptively treated with intravenous ganciclo-
vir or foscarnet.
The median time from transplant to ICU admission for all
admissions (n = 213) was 42 d (range 5 d to 55 years),
with recipients of MA Allo-HSCT being admitted to ICU
earlier than RI-conditioned patients (median 32 d compared
to 50 d, respectively, P = 00007).
During the study period, 552 patients underwent an Allo-
HSCT procedure; of these, 164 (30%) required 1 or more
ICU admission. Of the 164 patients, 125 (76%) had one sin-
gle ICU admission, and 39 (24%) required 2–4 admissions.
Table I. Characteristics of patients having one or more ICU admis-
sion after allogeneic HSCT (n = 164).
Characteristic
MA
N = 127
RI
N = 37 P value
Sex
Male 48 (38%) 17 (46%) 0446
Female 79 (62%) 20 (54%)
Age at (last) admission
Median (range), years 39 (11–60) 50 (23–66) 00001
Time since transplant
Median (range), days 32 (1–476) 69 (6–1989) 00007
Diagnosis
ALL 34 (27%) 0 00001
AML 36 (28%) 0
NHL 20 (16%) 20 (54%)
HL 5 (4%) 6 (16%)
CLL 0 4 (11%)
MF 1 (1%) 3 (8%)
CML 14 (11%) 3 (8%)
MDS 6 (5%) 0
MM 11 (9%) 1 (3%)
Donor stem cell source
Sib 66 (40%) 16 (10%)
UD 61 (37%)* 21 (13%)†
Number of ICU admissions
1 99 (78%) 26 (70%) 0592
2 17 (13%) 8 (22%)
3 8 (6%) 2 (5%)
4 3 (2%) 1 (3%)
Duration of ICU stay
Median (range) days 4 (0–52) 6 (0–21) 04451
ICU, intensive care unit; HSCT, haematopoietic stem cell transplan-
tation; ALL, acute lymphoblastic leukaemia; AML, acute myeloid
leukaemia; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma;
CLL, chronic lymphocytic leukaemia; MF, myelofibrosis; CML,
chronic myeloid leukaemia; MDS, myelodysplasia; MM, multiple
myeloma; Sib, matched sibling donor; UD, Unrelated Donor; RI,
Reduced Intensity.
*Includes 3 Haploidentical donors.
†Includes 1 umbilical cord blood donation.
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Despite an older median age of patients undergoing RI
Allo-HSCT compared to MA conditioning (age at time of
transplant: 47 vs. 36 years, respectively, P < 00001) only 37/
218 (17%) RI Allo-HSCT recipients were admitted to ICU at
least once compared to 127/334 (38%) following MA Allo-
HSCT (P < 0001). The ICU admission rate for the 1119
autologous stem cell transplants carried out at our centre
during the same period was 5%.
Indications for and characteristics of ICU admissions
Individual ICU admission characteristics including the reason
for admission, duration of ICU stay, number of organ sys-
tems supported during admission, APACHE II score and
other laboratory data are detailed in Table II.
The total number of ICU admissions described in Table II
was 213. The most frequent indication for admission were
sepsis (67%) and/or respiratory failure (55%). Indications for
admission were not mutually exclusive and patients were
often admitted with multiple factors. Ventilatory support was
required in 132 (62%) admissions. Mechanical ventilation
(MV) was required in a total of 107 admissions (50%),
including 49 (23%) where MV followed non-invasive ventila-
tion (NIV). During a further 25 admissions, NIV alone was
required (19%). In 44 admissions (21%) no mechanical or
vasoactive drug organ support was instituted.
Multilevel model stratification by patient was used to
assess the impact of conditioning intensity on median admis-
sion duration and APACHE score on admission. The median
duration of an ICU admission was 4 d (range 1–52), being
4 d for the MA Allo-HSCT group (range 0–52) and 6 d for
the RI All-HSCT group (range 0–21), P = 0345. The median
APACHE II score was 23 (range 4–51). There was no signifi-
cant difference in APACHE II score between the RI condi-
tioning and MA conditioning recipients (median 22 vs. 23,
respectively, P = 0646).
Short-term outcome: ICU survival by patient
When short-term outcome by patient (n = 164) was consid-
ered, 53 patients (32%) survived ICU (Table III). For
patients admitted to ICU more than once, median follow-up
and survival endpoints were measured at discharge from the
final admission.
The causes of death on ICU were recorded in Table III.
Pneumonia and other respiratory disorders combined (pneu-
monitis, lung injury and acute respiratory distress syndrome –
ARDS) were the cause of death in 44 patients (39%).
Overwhelming sepsis was the cause of death in 39 patients
(35%). The identifiable cause of death on ICU is often multi-fac-
torial and as such, the causes of death were not mutually
exclusive.
A number of variables affecting ICU survival were consid-
ered in more detail and are shown in Table IV. Despite MA
Allo-HSCT patients being admitted to ICU significantly
earlier in their transplant course, compared to recipients of
RI Allo-HSCT, no significant effect on ICU survival of prox-
imity of ICU admission to stem cell return (Day 0) was
observed (P = 0161).
The number of ICU admissions did not affect probability
of surviving to discharge (P = 0920), nor was it significantly
different between RI and MA patients. There was, however, a
trend to poorer prognosis for those survivors having had >1
admission to ICU (P = 0069).
Table II. Characteristics of all Allo-HSCT related ICU admissions
(n = 213).
Characteristic
N %
Median Range
Duration of ICU admission Days 4 1–52
N %
Reasons for admission (not
mutually exclusive)
Sepsis 142 67
Respiratory 117 55
Renal 27 13
Haemodynamic 26 12
Neurological 6 3
Observation 4 2
Post-operative 3 1
Liver failure 3 1
Other* 6 3
Unknown 3 1
Organ support (not mutually
exclusive)
Non-Invasive
ventilation
74 35
Mechanical
ventilation
107 50
Inotropes 96 45
Renal 56 26
No support 44 21
Indices on admission Median Range
Neutrophils
(9 109/l)
<05 0–18
Platelets
(9 109/l)
30 0–649
Urea (mmol/l) 99 18–45
Bilirubin
(mmol/l)
315 3–1081
APACHE II score Median Range
23 4–51
N %
4–10 5 2
11–20 64 31
21–30 102 49
31–40 34 16
>40 2 1
Not available 6 3
Allo-HSCT, allogeneic haematopoietic stem cell transplantation; ICU,
Intensive Care Unit; APACHEII, Acute Physiology and Chronic
Health Evaluation Score.
*Other reasons for admission (n = 6): post-cardiac arrest (n = 2),
poisoning, for open lung biopsy, post-liver biopsy, for endos-
copy.
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ICU survival was significantly better in patients admitted
after RI conditioning compared to MA conditioning (51%
vs. 27%, OR 2878; P < 001).
Further variables significantly affecting ICU survival by
patient on univariate analysis are detailed in Table IV. Inten-
sity of pre-transplant conditioning regimen, requirement for
organ support – including NIV alone, APACHE II score,
serum urea, and duration of ICU admission were all signifi-
cantly associated with adverse outcome. Interestingly, in our
study, duration of MV (and MV/NIV) was not associated
with a poorer outcome.
On multivariate analysis, MV and raised serum urea at the
time of admission remained associated with a poor short-
term outcome (P < 0001 and P = 0007, respectively).
Importantly, conditioning type also remained significant;
patients who underwent RI Allo-HSCT had a significantly
better ICU survival rate compared to those who received MA
conditioning (P = 0023) (Table IV).
It is likely that analysis by last admission inflates the
mortality incidence as earlier ICU admissions, which were
survived, were not included and the fatal admission is always
the last. However, no differences were observed on univariate
analysis when outcome was analysed by first admission to
ICU (data not shown). In addition, as indicated in Table I,
the number of admissions per patient were statistically simi-
lar between the MA and RI groups (P = 0592).
Long-term outcome
The overall survival rate at 1 and 5 years from time of ICU
admission for the whole cohort (i.e. including deaths in
ICU), was 19% and 17%, respectively (Fig. 1A).
As described above, 53/164 (32%) patients survived ICU
admission. For these patients, subsequent long-term survival
was excellent with 1- and 5-year survival rates of 61% and
51%, respectively, at a median follow-up for all patients of
43 months (range 8–101 months) (Fig. 1C). Median follow-
up for MA Allo-HSCT patients was 30 months (range
1–101) and 45 months (9–69) for RI Allo-HSCT patients.
No significant difference in causes of death was observed
(TRM or relapse) between the MA and RI groups. TRM at
5 years was 40% (95% CI: 21–58) in the MA Allo-HSCT
group and 35% (95% CI: 14–58) in the RI Allo-HSCT
group, P = 0566. Similarly, relapse mortality at 5 years was
11% for both groups (95% CI: 3–25 and 2–29, respectively),
P = 0975.
The improved survival for RI recipients admitted to ICU
remained significant with subsequent long-term follow-up
(P = 00055) (Fig. 1B) but this was due solely to differences
in immediate ICU survival (Fig. 1D). Similarly, requirement
for ventilatory support did not independently impact on sub-
sequent long-term survival in those who survived ICU
(Fig. 1E).
The long-term survival of ICU survivors was equivalent to
that observed for Allo-HSCT patients who did not require
admission to ICU peri- or post-transplant (data not shown).
Discussion
The admission of Allo-HSCT patients to intensive care
remains contentious based on published outcomes in this
patient group which are generally poor, even with more
recent studies demonstrating improvements (Naeem et al,
2006; Pene et al, 2006; Depuydt et al, 2011). There is a
perception that transfer to ICU may be futile and long-term
outcome poor, even if patients were to survive a critical ill-
ness episode. In our study, the ICU survival rate following
Allo-HSCT, measured at the time of final ICU admission for
those admitted more than once, was 32%; this compares
favourably with other published data in which ICU survival
was 30–51% (Pene et al, 2006; Lim et al, 2007; Bokhari et al,
2010; Depuydt et al, 2011).
During the study period, 30% of patients undergoing
Allo-HSCT required ICU admission with a significantly lower
admission rate following RI than MA conditioning, despite
the significantly older median age of RI recipients. Published
admission rates (11–40%) and reasons for admission (pre-
dominantly respiratory failure and/or sepsis) are comparable,
as is the severity of illness (Afessa et al, 1992; Faber-Lange-
ndoen et al, 1993; Rubenfeld & Crawford, 1996; Jackson
et al, 1998; Paz et al, 1998; Price et al, 1998; Soubani et al,
2004; Naeem et al, 2006). Invasive ventilation was required
Table III. ICU survival and causes of death for all 164 Allo-HSCT
patients.
% N
ICU survival
Total patients 164
Yes 32 53
No 68 111
ICU survival
Conditioning
MA 27 34
RI 51 19
Cause of death in ICU (Not mutually exclusive)
Total deaths 111
Sepsis 35 39
MOF 27 30
Respiratory 39 44
Invasive fungal infection 5 6
GvHD 5 5
Other* 14 15
ICU, Intensive Care Unit; Allo-HSCT, allogeneic haematopoietic
stem cell transplantation; MOF, Multi Organ Failure; GvHD, Graft-
versus-host disease; RI, Reduced Intensity; MA, Myeloablative.
*Other causes of death on ICU = relapse (n = 2), cardiac arrest
(n = 2), gastrointestinal bleed (n = 2), pulmonary haemorrhage
(n = 1), intracerebral haemorrhage (n = 1), hepatic failure (n = 1),
graft failure (n = 1), Post-transplant lymphoproliferative disorder
(n = 1), left ventricular perforation during pericardial drain insertion
(n = 1), ciclosporin-related thrombotic thrombocytopenic purpura
(n = 1).
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in 50% of admissions and the APACHE II score was >20 in
65% of admissions. For comparison, the median APACHE II
score for all UK ICU admissions is 165 (Harrison et al,
2004), and was 20–25 in international trials of sepsis in ICU
(Bernard et al, 2001; Brunkhorst et al, 2008).
The factors most consistently associated with poor ICU
outcome in HSCT patients are multi-organ failure and
mechanical ventilation (Afessa et al, 1992; Rubenfeld &
Crawford, 1996; Hinds et al, 1998; Soubani et al, 2004),
raised bilirubin (Jackson et al, 1998; Price et al, 1998; Afessa
et al, 2003), increasing age (Faber-Langendoen et al, 1993;
Epner et al, 1996; Hinds et al, 1998; Darmon et al, 2002;
Rabe et al, 2004), and increased APACHE or Sequential
Organ Failure Assessment (SOFA) scores (Knaus et al, 1985;
Afessa et al, 2003; Depuydt et al, 2004; Cornet et al, 2005;
Cherif et al, 2007). Our results corroborate these findings
with the notable exception of elevated bilirubin, which was
not significantly associated with a negative ICU outcome.
This may reflect the fact that the majority of patients under-
went T-cell depleted Allo-HSCT, with a consequently low
incidence of GvHD. As with other studies (Paz et al, 1993,
1998; Epner et al, 1996; Rubenfeld & Crawford, 1996; Lim
et al, 2007), we found that ICU survival in our cohort of
patients was affected adversely by the number of organs
supported during ICU admission and the need for ventila-
tory support (21% compared to 87% when no ventilatory
support was required). Unlike previous studies, we identified
NIV as a statistically significant independent predictor of
ICU survival, again reflecting the prognostic importance of
respiratory failure.
RI conditioning regimens have reduced TRM and permit-
ted the use of potentially curative transplants in older
Table IV. Variables influencing ICU survival (n = 164 patients).
Effects on ICU survival (univariate analysis) OR (95% CI) P value N
Reason for admission
Sepsis 0708 (0367–1367) 0304 27/93 (29%)
Respiratory 0543 (0281–1053) 0071 24/91 (26%)
Renal 0422 (0135–1315) 0137 4/22 (18%)
Haemodynamic 0451 (0144–1415) 0172 4/21 (19%)
Neurological 0692 (0070–6818) 0753 1/4 (25%)
Donor
UD versus Sib 0946 (0491–1820) 0867 26/79 (33%) vs. 27/58 (32%)
Conditioning
RI versus MA 2887 (1357–6142) 0006 19/37 (51%) vs. 34/127 (27%)
Organ support
NIV 0390 (0178–0856) 0019 13/50 (21%)
MV 0093 (0042–0208) <0001 11/83 (12%)
Inotropes 0176 (0083–0373) <0001 13/87 (15%)
Renal 0243 (0100–0590) 0002 7/52 (13%)
No ventilatory support versus NIV only versus MV  NIV 0240 (0147–0389) <0001 23/33 (70%) vs. 7/37 (37%) vs. 11/94 (12%)
Number of organs supported
0 vs. 1 vs. 2 vs. 3 0385 (0273–0541) <0001 33/33/45/45
Neutrophil count 1013 (0931–1102) 0768
Platelet count 1006 (1000–1011) 0062
Urea 0930 (0885–0977) 0004
Bilirubin 1000 (0996–1003) 0978
APACHE II 0930 (0883–0980) 0006
Duration of ICU stay 0952 (0907–0998) 0042
Duration of MV 0982 0694
Combined duration of NIV  MV 0945 0170
Year of ICU admission 1102 0072
Number of ICU admissions 0976 (0611–1559) 0920
Effects on ICU survival (multivariate analysis) OR (95% CI) P value
MV 0071 <0001
Urea 0931 0007
Conditioning intensity 327 0023
ICU, intensive care unit; OR, odds ratio; 95% CI, 95% confidence interval; UD, unrelated donor; Sib, matched sibling donor; RI, reduced inten-
sity; MA, myeloablative; NIV, non-invasive ventilation; MV, mechanical ventilation; APACHEII, Acute Physiology and Chronic Health Evaluation
Score.
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patients (Chakraverty et al, 2002; Bacigalupo et al, 2004;
Morris & Mackinnon, 2005; Craddock, 2008; Thomson et al,
2010; Peggs et al, 2011). In the UK the majority of allogeneic
transplants performed in adults now utilize RI conditioning
(K. Kirkland, BSBMT Data Registry, personal communica-
tion). The effect of this on ICU survival has not previously
been clearly reported because RI Allo-HSCT recipients
accounted for too few patients in previous studies to draw
meaningful conclusions about the impact of conditioning
intensity on ICU survival (Pene et al, 2006; Lim et al, 2007;
Depuydt et al, 2011). Our study included 37 (23%) patients
who had undergone RI conditioning and we found that con-
ditioning intensity significantly influenced ICU survival
despite there being no significant difference in median
APACHEII score or requirement for MV.
There few published large studies concerning long-term
survival of Allo-HSCT patients after ICU discharge. We
observed a 5-year overall survival of 51% for patients surviv-
ing ICU admission. This important finding from a large
study supports the position that critically ill Allo-HSCT
patients should be considered for ICU support, as excellent
long-term survival is potentially achievable.
Critical care support and management have improved
over recent years as a result of early recognition and inter-
vention in sepsis (Rivers et al, 2001), improved understand-
ing and management of ARDS, increased use of NIV
(Azoulay et al, 2001), and a move to admit sick patients to
the ICU before organ failure becomes firmly established
(Bokhari et al, 2010). The improved survival rates in more
recent studies may be in part due to these changes, and in
part to better patient selection and management of the
terminal phase of illness on the ward rather than in ICU
(Naeem et al, 2006). Year of admission to ICU had a trend
to significance only in the univariate analysis performed on
our study cohort (P = 007), but this was non-significant on
subsequent multivariate analysis. It is likely that much larger
studies would be required to demonstrate such an effect ‘of
era’ on improving outcomes, as changes in supportive care
are confounded by changes in transplant protocols. Clearly,
the decision to admit to ICU requires an accurate assessment
of the underlying condition, prognosis and reversibility of
illness (Azoulay et al, 2001).
Application of the findings from our retrospective single
centre study to different patient cohorts and different centres
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Fig 1. (A) Kaplan–Meier survival curve for all patients admitted to the intensive care unit (ICU) (including deaths on ICU), n = 164. (B) Kaplan–
Meier survival curve for all patients: Overall Survival after last admission by transplant conditioning intensity (Survival curves compared using
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should be performed with caution at present. However, ours
is one of the largest studies examining the survival of
patients admitted to ICU following Allo-HSCT with 213 con-
secutive admissions over an 115-year period. It includes
long-term follow-up data beyond 1 year post-ICU discharge,
and this demonstrates excellent subsequent long-term
survival. It is also one of the first studies looking at ICU sur-
vival after RI allogeneic transplants.
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